RE-Vana Therapeutics CEO Michael J. O’Rourke announces two new team appointments:
Following our successful $11.9M Series A in November 2022, Re-Vana Therapeutics is delighted to further strengthen our team with two new appointments as we develop our sustained release biologics platforms:
Patrick Ruane is appointed Chief Operating Officer
Raj Thakur will join on a 2 year sabbatical from Queens University Belfast as Chief Technology Officer
Congrats to both Patrick and Raj
New Re-Vana career opportunities in Program Management, Quality Control, Biologics Development and Technical Services will be announced over the coming weeks.